Delivery : 1-2 Working Days
Report Code: LS10998
Category : Pharmaceuticals
Insomnia therapeutic pipeline analysis is expected to experience vast growth in future, with the increasing level of stress being the major contributor for the rising prevalence of the disease. Some of the other major factors driving the pipeline for insomnia include lifestyle diseases, smoking, alcohol and tobacco consumption and increasing health awareness. According to the data by American Academy of Sleep Medicine, every year eight million people suffer from insomnia in the U.S. It is believed that the disease is more commonly found in females as compared to males.
Insomnia is an intricate condition which involves difficulty in sleeping. It is categorized into two types based on its duration, acute insomnia and chronic insomnia. Acute insomnia is short-termed and frequently happens because of the increasing stress in. This type of insomnia does not require treatment and resolves itself. Chronic insomnia is a severe problem when a person is unable to sleep for at least three nights per week and this lasts for more than three months. Chronic insomnia is caused by several factors including changes in environment, work stress, certain medications and other clinical diseases. Sometimes, chronic insomnia is also linked with other psychiatric problems, which makes it difficult to diagnose. Some of the other causes of insomnia include asthma, arthritis, hyperthyroidism, parkinson’s disease, lower back pain, chronic pain, gastrointestinal problems and nasal allergies. Some medications such as medicines prescribed for high blood pressure, asthma, birth control, heart disease and nasal allergies, can also cause insomnia. Common symptoms of insomnia include tiredness, mood swings, change in behaviour, problems in relationships and others. Insomnia is diagnosed by physical examination and analysing the symptoms in an individual. Insomnia is treated by using several approaches which includes cognitive behavioral therapy, relaxation training and medication treatment. Some marketed medicines for insomnia includes non-benzodiazepine hypnotics, melatonin receptor agonists and benzodiazepine hypnotics.
Many companies are developing drug for treating insomnia which has shown promising result in clinical trials. Eisai Co., Ltd. is developing a drug by the name Lemborexant, for the improvement in patients of insomnia. Lemborexant is being developed as a small molecule which acts as an orexin receptor antagonists. It has currently in Phase III clinical stage of development. Actelion Pharmaceuticals Ltd. is currently developing ACT 541468, which is in Phase II clinical stage of development. ACT 541468 is also being developed as a small molecule and acts as an orexin receptor antagonists. Evotec AG is developing EVT-201 for treatment of insomnia patients. It is currently in Phase II stage of development and acts as a small molecule that modulates GABA A receptors. Bristol-Myers Squibb Company is developing Lumateperone, which is in Phase II clinical trial for treatment of insomnia, and is a serotonin protein inhibitor.
Some of the companies having a pipeline of insomnia therapeutics include Eisai Co., Ltd., Actelion Pharmaceuticals Ltd., Ache Laboratorios Farmaceuticos S.A., Merck Sharp & Dohme Corp., Evotec AG, Bristol-Myers Squibb Company, Johnson & Johnson, Alexza Pharmaceuticals, Inc., Reviva Pharmaceuticals Inc., Shionogi & Co., Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Neurim Pharmaceuticals Ltd., Heptares Therapeutics Limited, Intra-Cellular Therapies, Inc.